| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 6774 | 2011 |
| Final version of 2009 AJCC melanoma staging and classification CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ... Journal of clinical oncology 27 (36), 6199, 2009 | 4212 | 2009 |
| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ... Science 350 (6264), 1079-1084, 2015 | 1059 | 2015 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1012 | 2015 |
| Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors B Routy, E Le Chatelier, L Derosa, CPM Duong, MT Alou, R Daillère, ... Science 359 (6371), 91-97, 2018 | 827 | 2018 |
| Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 806 | 2014 |
| Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... The lancet oncology 16 (5), 522-530, 2015 | 741 | 2015 |
| TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility R van Horssen, TLM ten Hagen, AMM Eggermont The oncologist 11 (4), 397-408, 2006 | 670 | 2006 |
| Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... New England Journal of Medicine 375 (19), 1845-1855, 2016 | 643 | 2016 |
| Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial AMM Eggermont, S Suciu, M Santinami, A Testori, WHJ Kruit, J Marsden, ... The Lancet 372 (9633), 117-126, 2008 | 625 | 2008 |
| Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable … A Hauschild, SS Agarwala, U Trefzer, D Hogg, C Robert, P Hersey, ... J Clin Oncol, Epub ahead of print, PMID 19349552, 2009 | 613 | 2009 |
| Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The lancet oncology 12 (10), 933-980, 2011 | 598 | 2011 |
| Improved endpoints for cancer immunotherapy trials A Hoos, AMM Eggermont, S Janetzki, FS Hodi, R Ibrahim, A Anderson, ... Journal of the National Cancer Institute 102 (18), 1388-1397, 2010 | 522 | 2010 |
| Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative … AM Eggermont, HS Koops, JM Klausner, BB Kroon, PM Schlag, D Liénard, ... Annals of surgery 224 (6), 756, 1996 | 521 | 1996 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118, 2014 | 483 | 2014 |
| Gene expression profiling of primary cutaneous melanoma and clinical outcome V Winnepenninckx, V Lazar, S Michiels, P Dessen, M Stas, SR Alonso, ... Journal of the National Cancer Institute 98 (7), 472-482, 2006 | 478 | 2006 |
| Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ... CA: a cancer journal for clinicians 67 (6), 472-492, 2017 | 447* | 2017 |
| Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a … AM Eggermont, H Schraffordt Koops, D Liénard, BB Kroon, AN van Geel, ... Journal of Clinical Oncology 14 (10), 2653-2665, 1996 | 441 | 1996 |
| Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot, J Adam, I Vitale, ... Nature medicine 20 (11), 1301, 2014 | 434 | 2014 |
| Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ... Annals of Oncology 27 (4), 559-574, 2015 | 411 | 2015 |
